What is NarcConvert?
NarcConvert is a program to convert narcotic doses from one drug to another. You may pick up to two different drugs and have them converted to and equivalent dose of another narcotic.
An iPhone or iPod Touch OS v2.0
Usage is simple. Just select either "Drug 1" or "Drug 2" or both. Fill in a dose for each and then select a drug for "Drug3". The equivalent dose will be updated automatically. The equivalent dose used for the calculations is listed in parenthesis next to the drug name. You may also change the equivalent doses used for each medication as well as delete existing drugs or add new ones.
11/2012 - removed from app store. I lost the source code and have no immediate plans of updating for current IOS compatibility.
Version 1.0 - 10/25/08 - Initial release
While this program can be useful for converting between doses of different narcotics, it should only be used as a guide. Studies differ on equivalent dosages and patient responses vary. The bottom line is don't replace clinical decision making with a number from a computer program!
Drug - Equivalent Dose
Buprenorphine Inj - 0.4 mg
Butorphanol Inj - 2 mg
Codeine Inj - 120 mg
Codeine Oral - 200 mg
Fentanyl Inj - 0.1 mg
Hydrocodone Oral - 30 mg
Hydromorphone Inj - 1.5 mg
Hydromorphone Oral - 4 mg
Hydromorphone Rectal - 3 mg
Levorphanol Inj - 2 mg
Levorphanol Oral - 4 mg
Meperidine Inj - 75 mg
Meperidine Oral - 300 mg
Morphine Inj - 10 mg
Morphine Oral - 30 mg
Morphine Rectal - 30 mg
Nalbuphine Inj - 10 mg
Nalbuphine Oral - 50 mg
Oxycodone Oral - 30 mg
Oxymorphone Inj - 1 mg
Oxymorphone Rectal - 10 mg
Propoxyphene Nap Oral - 200 mg
Sufentanil Inj - 0.01 mg
- Chan GLC and Matzke, GR. Effects of renal Insufficiency on that pharmacokinetics and pharmaco-dynamics of opioid analgesics. Drug Intell Clin Pharm. 1987:21:773-83.
- Clotz MA and Nahata MC. Clinical uses of fentanyl, sufentanil, and affentanil. Clin Pharm. 1991;10:581-93.
- Crews JC. Clinical efficacy of methadone in patients refractory to other mu-receptor agonist analgesics for management of terminal cancer pain. Cancer. 1993 (Oct):2266-72.
- Foley KM. The treatment of cancer pain. Now Eng J Med. 1965; 313(2):84-95.
- Jaffe JH. Martin WR. Opioid analgesics and antagonists. In: Gilman AG. Rall TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics, 8th ed. New York; Pergamon Press: 1990; 485-521.
- Lipman AGL. Opiold analgesics in the management of cancer pain. Am J Hosp Care. 1989; Jan-Feb:13-23.
- Olin BR, ed. Drug facts and comparisons. St. Louis; Facts and Comparisons: 1994.
- OSUMC standard clinical practice.
- Parab PV, Ritschel WA, Coyle DE, et al. Pharmacokinetics of hydromorphorm after intravenous, peroral and rectal administration to human subjects. Biopharm Drug Disp. 1988: 9:187-99.11.Pohyia R, Vainio A. Kalso E. A review of oxyoodone's clinical pharmacokinetics and pharmaco-dynamics. J Pain Symptom Manage 1993;8:63-7.
- Product package Inserts.
- U.S. Department of Health and Human Services Agency for Health Care Policy and Research, Clinical practice guideline: acute pain managernent: operative or medical procedures and trauma. February 1992.